Peptides for Neuroscience Reference

4 research peptides are currently studied for neuroscience reference. This guide ranks them by evidence strength and covers their mechanisms, safety profiles, and current clinical status.

Substance P is an 11-amino-acid neuropeptide (sequence: Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2, MW ~1347.6 g/mol) that is integral to the tachykinin family. Its widespread distribution in both central and peripheral nervous systems underscores its pivotal role in neurotransmission and neuromodulation, particularly in pain pathways, inflammatory responses, and emesis. As the primary endogenous agonist of the neurokinin-1 receptor (NK1R), Substance P has been extensively studied, leading to the development of NK1R antagonists like aprepitant (Emend), which is FDA-approved for the treatment of chemotherapy-induced nausea and vomiting. Research indicates that NK1R antagonists effectively mitigate the effects of Substance P, thereby providing a therapeutic avenue for managing emesis. However, the implications of Substance P in chronic pain conditions require further exploration, as current studies primarily focus on its acute effects.

Neuropeptide Y (NPY) is a 36-amino-acid peptide (MW ~4271.7 g/mol) recognized as one of the most abundant neuropeptides in the mammalian brain. NPY is primarily known for its orexigenic properties, significantly influencing appetite regulation and energy balance. Beyond its role in energy homeostasis, NPY is implicated in modulating stress responses, anxiety levels, circadian rhythms, and cardiovascular functions. It acts through a family of G-protein-coupled receptors (Y1, Y2, Y4, Y5), making it a critical target for therapeutic interventions aimed at metabolic and psychiatric disorders. While NPY itself is not a therapeutic agent, its regulatory functions position it as a promising candidate for drug development, particularly in the context of obesity and anxiety disorders. Nevertheless, the complexity of NPY signaling pathways presents challenges in translating preclinical findings into clinical applications.

Vasoactive Intestinal Peptide (VIP) is a 28-amino-acid neuropeptide (MW ~3326.8 g/mol) that plays diverse roles in the central and peripheral nervous systems, as well as in other tissues such as the lungs and gastrointestinal tract. Known for its vasodilatory and bronchodilatory effects, VIP also exhibits significant immunomodulatory properties. The synthetic analog aviptadil (RLF-100) has been evaluated in clinical trials for its potential benefits in treating COVID-19-associated acute respiratory distress syndrome (ARDS) and pulmonary arterial hypertension. Preliminary results suggest that VIP may confer protective effects in lung inflammation and injury, although further studies are needed to establish its efficacy and safety profile in broader patient populations. Additionally, VIP's diagnostic utility in identifying VIPoma underscores its relevance in both clinical and research settings, yet the full spectrum of its therapeutic applications remains to be elucidated.

Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) exists in two biologically active forms: PACAP-38 (38 amino acids, MW ~4534.3 g/mol) and PACAP-27 (27 amino acids). PACAP-38 predominates in the brain and is part of the VIP/secretin/glucagon superfamily, sharing notable sequence homology with VIP. This neuropeptide has emerged as a potent neuroprotective and neurotrophic agent, with burgeoning research exploring its implications in migraine pathophysiology, post-traumatic stress disorder (PTSD), and neurodegenerative diseases. While PACAP's neuroprotective properties suggest potential therapeutic applications, no approved therapeutics currently exist. The complexity of PACAP signaling pathways and its multifaceted roles in various physiological processes necessitate further investigation to clarify its therapeutic potential and to develop effective interventions targeting PACAP-related mechanisms.